The association between fibrotic diseases and treatment resistant hypertension in England

Aims

Multimorbidity has been identified as a research priority in recent years; fibrosis (progressive organ scarring) is one mechanism that may underpin multimorbidity. Some studies suggest hypertension could be fibrotic, particularly severe hypertension (uncontrollable with medications); however, it is not currently known whether severe hypertension is associated with fibrotic conditions. The objective is to investigate whether treatment-resistant hypertension is associated with fibrotic conditions.

Methods and results

We used the Clinical Practice Research Datalink Aurum primary care database to define a cohort of people with hypertension during 2015. We determined the percentage of people who had conditions with fibrotic manifestations and explored differences respective to hypertension control. We applied multivariable logistic regression to analyse associations (P < 0.001) between hypertension control and each fibrotic condition, respectively. Of 1 340 495 people with hypertension during 2015, 83.50% (n = 1 119 333) had managed hypertension either by lifestyle or by medication; 16.50% (n = 221 162) had treatment-resistant hypertension. Fibrotic conditions were more common {75.40% [95% confidence interval (CI): 75.20–75.60] vs. 68.90% (95% CI: 68.81–70.01)} in people with treatment-resistant hypertension compared with those with managed hypertension. We found that treatment-resistant hypertension was associated with cardiomyopathy (ORadj: 1.85, 95% CI: 1.81–1.90), both Type 1 and Type 2 diabetes (ORadj: 1.49, 95% CI: 1.44–1.55, ORadj: 1.61, 95% CI: 1.60–1.63, respectively), liver fibrosis (ORadj: 1.52, 95% CI: 1.46–1.58), valve fibrosis (ORadj: 1.41, 95% CI: 1.37–1.44), and urinary fibrosis (ORadj: 1.41, 95% CI: 1.36–1.47).

Conclusion

The proportion of people with fibrotic conditions was greater in those with treatment-resistant hypertension than managed hypertension. The identified associations between treatment-resistant hypertension and fibrotic conditions may point to common disease pathways, which should be further explored to understand shared mechanisms.